Polypeptide Conjugate Salt-Enhanced Coupling Yield

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preparing physiologically active polypeptide conjugates face challenges such as low production yield, high production costs, and immune reactions, particularly when using PEGylation or fusion proteins, which do not significantly extend the blood half-life of peptide drugs like insulin, leading to frequent injections and patient discomfort.

Innovation Solution

A method involving the covalent bonding of a physiologically active polypeptide with a non-peptidyl polymer and an immunoglobulin constant region using a salt in the coupling reaction to enhance yield and purity, specifically using a non-peptidyl polymer with functional groups like aldehyde or maleimide derivatives and optimizing salt concentrations and reaction conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If PEGylation method is used to stabilize protein drugs, then blood circulation time is extended, but production yield is significantly lowered and reactivity is reduced

Engineering Contradiction:

Improveblood circulation timeVSAvoidproduction yield

Core Design Contradiction:

Duration of action of moving objectVSProductivity

Solution Approach 1:

The patent changes the chemical parameters of the coupling reaction by using alternative reagents (WSC, HOBt) and optimizing pH conditions to improve reaction efficiency and yield while maintaining the PEGylation approach for extending blood circulation time

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces a two-stage coupling process with intermediate purification steps, using the polymer-conjugated peptide as an intermediate product that can be isolated and then further conjugated with the immunoglobulin constant region, thereby improving overall reaction yield

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of moving object

If fusion protein method is used to extend blood half-life, then stability is improved, but titer is low and blood half-life extension is not remarkable

Engineering Contradiction:

Improveblood half-lifeVSAvoidtiter

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The patent divides the conjugation process into two separate stages: first conjugating the polymer with the peptide, then conjugating the immunoglobulin constant region with the polymer-conjugated peptide. This segmentation allows optimization of each step independently, improving overall efficiency and maintaining high titer while extending blood half-life

Inventive Principle:

Principle #1Segmentation

3Duration of action of moving object

If peptide linkers are used to maximize blood half-life effect, then circulation time is extended, but immunological reactions may be induced

Engineering Contradiction:

Improveblood half-lifeVSAvoidimmunological reaction

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent uses a non-peptidyl polymer (polyethylene glycol) as a linker instead of peptide linkers. This disposable-like approach uses a simple, inert polymer that does not induce immunological reactions, effectively extending blood half-life without the harmful effects of peptide-based linkers

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

4Duration of action of moving object

If high molecular weight PEG is used to increase circulation time, then molecular weight increases, but reactivity with peptides is lowered

Engineering Contradiction:

Improvecirculation timeVSAvoidreactivity

Core Design Contradiction:

Duration of action of moving objectVSManufacturing precision

Solution Approach 1:

The patent performs preliminary activation of the PEG polymer with N-hydroxysuccinimide and carbodiimide reagents before conjugation with the peptide. This preliminary action creates highly reactive intermediates that overcome the low reactivity issue of high molecular weight PEG, enabling efficient conjugation while maintaining the circulation time extension benefit

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the production of high-purity, long-acting formulations of physiologically active polypeptides with improved blood stability and reduced production costs, enhancing the blood half-life of drugs like insulin, thereby reducing the frequency of injections and improving patient compliance.

Implementation Method 1

reacting the reaction mixture of step (1) with the other of the physiologically active polypeptide or the immunoglobulin constant region in the presence of a salt

Methodology Applied

Scientific EffectCoupling reaction: Chemical Bonding

Data Source

PatentUS10660940B2Preparation method for high-yield production of physiologically active polypeptide conjugate

Publication Date: 2020.05.26 HANMI PHARM CO LTD

AI summary

A method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond are disclosed. The method enables an efficient preparation of a physiologically active polypeptide conjugate, in which a salt is used in a coupling reaction to improve the problem of low production yield during preparation of the physiologically active polypeptide conjugate.